|
Jun 23
|
DoorDash, AMD upgraded: Wall Street's top analyst calls
|
|
Jun 20
|
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
|
|
Jun 20
|
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
|
|
May 26
|
EMA validates Soleno’s application for Prader-Willi syndrome treatment
|
|
May 23
|
Soleno Therapeutics seeking regulatory approval in treatment of PWS
|
|
May 23
|
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
|
|
May 22
|
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
|
|
Apr 23
|
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
|
|
Apr 14
|
Soleno Therapeutics Announces VYKAT(TM) XR Launch
|
|
Apr 1
|
High Growth Tech Stocks To Watch In The US April 2025
|
|
Mar 30
|
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?
|
|
Mar 29
|
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday?
|
|
Mar 28
|
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday?
|
|
Mar 27
|
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
|
|
Mar 27
|
Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger
|
|
Mar 27
|
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
|
|
Mar 27
|
Soleno stock skyrockets on FDA drug approval
|
|
Mar 27
|
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
|
|
Mar 26
|
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
|
|
Mar 3
|
Exploring US High Growth Tech Stocks In March 2025
|